National Heart, Lung, And Blood Institute Clinical Proteomics Working Group report.
The National Heart, Lung, and Blood Institute (NHLBI) Clinical Proteomics Working Group was charged with identifying opportunities and challenges in clinical proteomics and using these as a basis for recommendations aimed at directly improving patient care. The group included representatives of clinical and translational research, proteomic technologies, laboratory medicine, bioinformatics, and 2 of the NHLBI Proteomics Centers, which form part of a program focused on innovative technology development. This report represents the results from a one-and-a-half-day meeting on May 8 and 9, 2003. For the purposes of this report, clinical proteomics is defined as the systematic, comprehensive, large-scale identification of protein patterns ("fingerprints") of disease and the application of this knowledge to improve patient care and public health through better assessment of disease susceptibility, prevention of disease, selection of therapy for the individual, and monitoring of treatment response.
Granger
Christopher B
CB
Duke University Medical Center, Box 3409, Durham, NC 27710, USA.
Van Eyk
Jennifer E
JE
Mockrin
Stephen C
SC
Anderson
N Leigh
NL
D018070:Biological Specimen Banks / Q000458:organization & administration; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000235:genetics / Q000517:prevention & control; D002986:Clinical Trials as Topic; D019295:Computational Biology; D003299:Cooperative Behavior; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D008297:Male; D009316:National Institutes of Health (U.S.) / Q000458:organization & administration; D010330:Patents as Topic; D017149:Private Sector; D040901:Proteomics / Q000331:legislation & jurisprudence / Q000379:methods; D012106:Research / Q000458:organization & administration; D012306:Risk; D014481:United States